Clinical Trials Logo

Unresectable Breast Cancer clinical trials

View clinical trials related to Unresectable Breast Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06386263 Recruiting - Clinical trials for Metastatic Breast Cancer

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

HER-TEMPO
Start date: April 22, 2024
Phase:
Study type: Observational

Trastuzumab deruxtecan (T-DXd) has been studied in multiple global prospective DESTINY-Breast trials and has a marketing authorization from Health Canada for patients with HER2-positive metastatic breast cancer (mBC) and HER2-low mBC, respectively. Multiple stakeholders, including clinicians, patients, regulators, and healthcare decision makers, are interested in real-world treatment-related outcomes in order to better represent the effectiveness of therapies in routine care settings.

NCT ID: NCT05945732 Recruiting - Clinical trials for Metastatic Breast Cancer

DESTINY Breast Respond HER2-low Europe

Start date: October 24, 2023
Phase:
Study type: Observational

Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.